
    
      Prior to the implementation of Amendment 1/UK3 the study consisted of 3 phases -
      pre-randomization up to 35 days, up to 84 days placebo-controlled treatment and a 28-day
      observational follow up. After the implementation of Amendment 1/UK3, the study consisted of
      4 phases - pre-randomization up to 35 days, up to 84 days treatment in the placebo controlled
      treatment phase, up to 84 days treatment in the active treatment extension phase and a 28 day
      follow up. Participants who completed the treatment phase prior to implementation of
      amendment 1/UK3 did not have the option of entering the extension phase.
    
  